|
| |
Image Results
Loading...
Loading...
ELOXATIN Pages on BioPortfolio:
|
Cytotoxics remain standard bearers
As a result, Datamonitor expects sales of Taxotere, Eloxatin and Gemzar to drop 21%, 7% and 18% annually between 2010 and 2014 respectively, ...
http://www.bioportfolio.com/news/datamonitor_145.htm...
|
BioPortfolio Limited Cancer Market Trends 2008 - 2012
Eloxatin (oxaliplatin). Chapter 5 Key companies. Major cancer players. Leading companies ... Figure 47: Eloxatin (oxaliplatin) forecast sales, 2003-2012 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_592.html...
|
BioPortfolio Limited Pipeline Insight: Colorectal Cancer - Growing ...
Table 11: Ability of Eloxatin to meet unmet needs in the second-line treatment of metastatic colorectal cancer (CRC), 2009 32 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_2115.html...
|
BioPortfolio Limited Oncology Market Leaders - Analyses and ...
Table 3.14 Eloxatin Market Sales Forecast, 2008-2023. Table 3.15 Global Sales of Arimidex, 2004-2007 .... Figure 3.13 Global Sales of Eloxatin, 2004-2007 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_468.html...
|
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming ...
This is in part, driven by the sales of Eloxatin (oxaliplatin; Sanofi-Aventis) and Camptosar. However, by 2017, the antimetabolite brands class are set to ...
http://www.bioportfolio.com/cgi-bin/acatalog/Commercial-Insi...
|
BioPortfolio News: AETERNA ZENTARIS INC. - AEterna Zentaris ...
Patients must have failed available therapy including 5-fluorouracil (5-FU), oxaliplatin (Eloxatin(R)), irinotecan, bevacizumab (Avastin(R)) and, ...
http://www.bioportfolio.com/news/AEterna-Zentaris-Partner-Ke...
|
Cancer Market Trends and Emerging Therapies
1 Dec 2005 ... 4.3.1 Eloxatin 4.3.1.1 Market Impact 4.3.2 Camptosar 4.3.2.1 Market Impact 4.3.3 Xeloda .... Table 4.5 Sales of Eloxatin 2000-2005 ...
http://www.bioportfolio.com/biotech_news/Arrowhead_Publisher...
| Results from other life science and pharmaceutical sites:
Oxaliplatin - Wikipedia, the free encyclopedia
Eloxatin gained European approval in 1996 (firstly in France) and approval ... Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin or by ...
http://en.wikipedia.org/wiki/Oxaliplatin...
|
Questions and Answers about Eloxatin (oxaliplatin for injection)
1 Jul 2009 ... Eloxatin is a platinum-based anticancer drug. It is the platinum that destroys the cancer cells. The active ingredient in Eloxatin is ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...
|
Oxaliplatin (Eloxatin)
In January 2004, the FDA approved Eloxatin (oxaliplatin for injection) in combination with 5-FU/LV for the first-line treatment of advanced colorectal ...
http://www.aetna.com/cpb/medical/data/600_699/0683.html...
|
Eloxatin Information
18 Jun 2009 ... On January 9, 2004, the Food and Drug Administration announced the approval of Eloxatin (oxaliplatin) injection for the initial treatment of ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...
|
eloxatin (oxaliplatin) solution, concentrate [sanofi-aventis US ...
ELOXATIN (oxaliplatin injection) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic ...
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7135...
|
British Journal of Cancer - Raltitrexed-eloxatin salvage ...
Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic ... Oxaliplatin (Eloxatin®, Sanofi-Synthelabo S.p.A, Milan, Italy),
...
http://www.nature.com/bjc/journal/v94/n6/full/6603026a.html...
|
eloxatin (oxaliplatin) powder, for solution for intravenous use ...
These highlights do not include all the information needed to use eloxatin safely and effectively. See full prescribing information for eloxatin. ...
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5664...
|
EU Approvals: Eloxatin, Raptiva, Alimta, Xenical
28 Sep 2004 ... The European Commission has approved the following drugs for use in the European Union: oxaliplatin (Eloxatin), efalizumab (Raptiva), ...
http://www.medscape.com/viewarticle/490269...
|
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant ...
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, ...
http://www.ncbi.nlm.nih.gov/pubmed/16508631...
|
FDA Approvals: Doxil, Lower-Dose Duragesic, Eloxatin
10 Feb 2005 ... The FDA has approved a revised indication for doxorubicin HCl liposome injection (Doxil), a lower-dose fentanyl transdermal system ...
http://www.medscape.com/viewarticle/499214...
|
|
